Browsing by Author Buck, M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2011Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-studyBrown, Christopher; Veillard, Anne-Sophie; Buck, M; Dorum, Anne; Elit, Laurie; Floquet, A.; Kaminsky, M; Kimmig, R; Kurtz, J; Petru, E; Pujade-Lauraine, Eric; Reed, N; Scambia, G; Varsellona, N; Medicine Faculty Office; School of Public Health: NH&MRC Clinical Trials CentreOvarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study, Annals of Oncology, vol.22, 11, 2011,pp 2417-2423
2007Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group studyBeale, Philip; Harnett, Paul; Allan, S; Buck, M; Davies, T; De Souza, P; Fitzharris, B; Goldrick, A; Kalimi, G; Links, Matthew; Stuart-Harris, R; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead)Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study, International Journal Of Gynecological Cancer, vol.17,(2),2007,pp 359-366
2007Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01Beale, Philip; Gebski, Val; Buck, M; Fitzharris, B; Goldrick, A; Rischin, D; Stuart-Harris, R; Tinker, A. V.; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentrePhase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01, Gynecologic oncology, vol.104,(3),2007,pp 647-653
2011Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysisBoland, Amy L.; Brown, Christopher; Clarke, Stephen; Gebski, Val; Simes, Robert John; Yip, Sonia; Buck, M; Goldstein, David; Jeffrey, G. Mark; Lowenthal, Raymond M.; Ransom, David T.; Tebbutt, Niall C; van Hazel, Guy; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Kolling Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSingle-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis, European Journal of Cancer, vol.47, 12, 2011,pp 1826-1836